Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 04 Dec 2018 Results from 4 trials published in the Journal of Clinical Psychiatry
- 01 Sep 2009 Actual end date (Mar 2006) added as reported by ClinicalTrials.gov.
- 08 May 2008 Primary endpoint results presenetd at APA in May 2008